9
Views
12
CrossRef citations to date
0
Altmetric
Original Article

FR900506 (FK506) and 15-Deoxyspergualin (15-DSG) Modulate the Kinetics of Infiltrating Cells in Eyes with Experimental Autoimmune Uveoretinitis

, , &
Pages 43-51 | Received 27 Feb 1990, Published online: 07 Jul 2009
 

Abstract

In order to evaluate two new immunosuppressive agents, FR900506 (FK 506) and 15-Deoxyspergualine (15-DSG), the kinetics of infiltrating cells in the eyes of Lewis rats with experimental autoimmune uveoretinitis (EAU) were studied. Rats were immunized with retinal S-antigen and treated with different doses of either FK 506 or 15-DSG. The inflammatory ocular tissues obtained at various intervals during the process of EAU were examined using an immunoperoxidase technique. The results were compared with those eyes developing EAU without treatment or with suboptimal doses or a suboptimal dose of Cyclosporin (CsA). BothFK 506 and 15-DSG, like CsA, delayed the cellular kinetics during the course of EAU. However. FK 506 had the greatest effect on the kinetics of T lymphocyte subsets by causing the greatest increase in the recruitment time of the T suppressor/cytotoxic population. FK506 treatment resulted not only in the highest inhibition of expression of IL-2 receptors on T cells, but also in the prevention of the expression of MHC class II antigens on ocular resident cells. Treatment with 15-DSG resulted in general immunosuppression on various infiltrating inflammatory cells.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.